1	Symptom-based prediction model of SARS-CoV-2 infection developed from
2	self-reported symptoms of SARS-CoV-2-infected individuals in an online
3	survey
4	
5	
6	
7	Hansjörg Schulze <sup>1</sup> , Daniel Hoffmann <sup>2</sup> , Wibke Bayer <sup>1, *</sup>
8	
9	
10	<sup>1</sup> Institute for Virology, University Hospital Essen, University Duisburg-Essen, Hufelandstr.
11	55, 45147 Essen, Germany
12	
13	<sup>2</sup> Bioinformatics and Computational Biophysics, Faculty of Biology, University Duisburg-
14	Essen, Universitätsstr. 2, 45141 Essen, Germany
15	
16	* corresponding author:
17	Email: wibke.bayer@uni-due.de
18	phone: +49-201-723-83034
19	

# 20 Abstract

21 Background: Infections with the newly emerged severe acute respiratory syndrome virus 2 22 (SARS-CoV-2) have quickly reached pandemic proportions and are causing a global health 23 crisis. First recognized for the induction of severe disease, the virus also causes asymptomatic 24 infections or infections with mild symptoms that can resemble common colds. Since 25 infections with mild course are probably a major contributor to the spread of SARS-CoV-2, 26 better detection of such cases is important. To provide better understanding of these mild 27 SARS-CoV-2 infections and to improve information for potentially infected individuals, we 28 performed a detailed analysis of self-reported symptoms of SARS-CoV-2 positive and SARS-29 CoV-2 negative individuals. 30 Methods: In an online-based survey, 963 individuals provided information on symptoms 31 associated with an acute respiratory infection, 336 of the participants had tested positive for SARS-CoV-2 infection, 107 had tested negative, and 520 had not been tested for SARS-CoV-32 33 2 infection. 34 **Results:** The symptoms reported most frequently by SARS-CoV-2 infected individuals were 35 tiredness, loss of appetite, impairment of smell or taste and dry cough. The symptoms with the 36 highest odds ratios between SARS-CoV-2 positive and negative individuals were loss of 37 appetite and impairment of smell or taste. Based on the most distinguishing symptoms, we

38 developed a Bayesian prediction model, which had a positive predictive value of 0.80 and a

39 negative predictive value of 0.72 on the SARS-CoV-2 tested individuals. The model predicted

40 56 of 520 non-tested individuals to be SARS-CoV-2 positive with more than 75% probability,

41 and another 84 to be SARS-CoV-2 positive with probability between 50% and 75%.

42 Conclusions: A combination of symptoms can provide a good estimate of the probability of
43 SARS-CoV-2 infection.

44

# 45 Keywords

- 46 SARS-CoV-2, COVID-19, symptoms, mild disease course, Bayesian model, Bayes model,
- 47 prediction, symptom model

# 49 Background

50 The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus 51 associated with the coronavirus infectious disease 19 (COVID-19), at the end of 2019 [1] has 52 quickly developed into pandemic proportions and was declared a public health emergency of international concern by the World Health Organization on January 30<sup>th</sup> 2020 [2]. The first 53 54 infections in Europe occurred in Italy and Germany in late January 2020 [3]. By March 2020, 55 SARS-CoV-2 infection rose rapidly in many countries, and have started to do so again with the fall season in the northern hemisphere; as of November 6<sup>th</sup> 2020, more than 48 million 56 57 people have been infected by SARS-CoV-2, and more than 1.2 million SARS-CoV-2 related 58 deaths have been reported [4].

59 Due to the rapid rise in demand for SARS-CoV-2 diagnostic tests and a resulting shortness of 60 supplies, not all patients could be given access to SARS-CoV-2 testing in spring 2020, and a pre-screening was performed on the basis of symptoms, and prior residence in SARS-CoV-2 61 62 risk areas or prior contact to individuals who had tested SARS-CoV-2 positive. The lack of 63 access to testing led to many uncertainties for patients with cold symptoms. From the first 64 cases in China, the typical symptoms of SARS-CoV-2 infection were described as dry cough, 65 fever, and pneumonia [5, 6]. These first reports of symptoms associated with SARS-CoV-2 infection / COVID-19 were based on symptoms found in hospitalized patients with severe 66 67 disease. Notably, in the first reports on COVID-19, disease course was considered mild if 68 patients did not require ventilation. It soon became obvious though that many SARS-CoV-2 69 infected individuals experienced asymptomatic or now commonly considered non-severe 70 disease course that resembled common colds and did not require hospitalization [7]. Since the 71 hospitalized and critically ill patients were of the greatest concern in the early days of the 72 pandemic, the range of symptoms of SARS-CoV-2 infected individuals with mild symptoms 73 was not the focus of attention. In following studies, it has been found that many SARS-CoV-2

74	infected patients experienced altered or completely lost sense of smell and / or taste [8, 9],
75	which has since been regarded as a key indicator of SARS-CoV-2 infection.
76	To get a more detailed picture of the symptoms of SARS-CoV-2 infection, we created an
77	online questionnaire and invited both tested and untested individuals to report their symptoms.
78	The symptoms included in the survey comprised general symptoms such as fever, fatigue,
79	headache and joint or muscle pains, and more specific eye, nose, throat, respiratory and
80	gastrointestinal symptoms. The self-reported symptoms of SARS-CoV-2 positive- and
81	negative-tested individuals were then used to fit a Bayesian model, which was used to predict
82	probabilities of a SARS-CoV-2 infection of the non-tested survey participants.

# 84 Methods

#### 85 Data collection

- 86 Data were collected in an online questionnaire based on LimeSurvey software hosted on the
- 87 servers of the University of Duisburg-Essen. Participants of the online survey were recruited
- via public health offices of the city of Hamm (Northrhine-Westphalia, Germany), of the
- 89 administrative district Soest (Northrhine-Westphalia, Germany), of the administrative district
- 90 Hochsauerland (Northrhine-Westphalia, Germany) and the SARS-CoV-2 testing center in
- 91 Lünen, administrative district Unna (Northrhine-Westphalia, Germany), as well as via social
- 92 media. Participants were invited to complete the survey in case of a positive as well as
- 93 negative SARS-CoV-2 test result, and also if they had not been tested but had cold symptoms.
- 94 The data were collected between April  $6^{th}$  and September  $1^{st}$  2020.

#### 95 Data analysis

96 Data were analyzed using R (version 3.6.3) and RStudio software and fsmb, plyr, splyr,

97 tidyverse, randomForest, patchwork, rstanarm, ROCR, ggplot2, viridis and bayesplot

98 packages. Only data from individuals who had completed the survey were included in the

analysis.

100 For graphic representation of the survey results of tested individuals, data were sorted for the

101 SARS-CoV-2 test result, the severity of the SARS-CoV-2 symptoms and the severity of fever

102 using the tidyverse package, and a heatmap of the survey data was generated using ggplot2

103 package.

104 Frequencies of individual symptoms were calculated and visualized as heatmap using ggplot2

105 and viridis package. Odds ratios for individual symptoms were calculated as the conditional

106 maximum likelihood estimate with 90% confidence interval using the pairwise.fisher.test

107 command of R package fsmb, results were visualized using ggplot2.

Random Forest analysis of the survey data was performed using R package randomForest 4.614 [10] with default parameters. Importance of individual symptoms was characterized as
mean decrease of Gini index on random permutations of case labels.

111 A Bayesian regression model was fitted with R package rstanarm version 2.21.1 [11] using 112 the function stan glm with default priors, on all or 10 selected symptoms of the tested 113 individuals' data as indicated in the results section, using a posterior sample size of 4000. To 114 adjust for differences in the number of SARS-CoV-2 positive and negative tested participants, 115 the dataset from negative participants (n = 107) was increased by bootstrapping to match the 116 number of positive participants (n = 336). Bootstrapping was performed 4 times to exclude a 117 bias of the results, with similar outcome. The R package bayesplot [12] was used to confirm 118 the model validity by posterior predictive checks. Performance of the Bayesian and Random 119 Forest based models as ROC curves (true positive rate and false positive rate) and area under 120 the ROC curve were calculated with R package ROCR [13]. The numbers of true positives 121 (TP), false positives (FP), true negatives (TN) and false negatives (FN) was determined using 122 posterior predictions > 0.5 as positives and posterior predictions  $\le 0.5$  as negative; positive 123 predictive value (PPV) was calculated as PPV = TP / (TP + FP), negative predictive value 124 (NPV) was calculated as NPV = TN / (TN + FN). The credibility intervals for PPV and NPV 125 were calculated using the Voila online tool [14], which is based on a Bayesian classifier 126 uncertainty estimate method [15].

For prediction of SARS-CoV-2 infection in untested individuals, the Bayesian model was applied to the dataset from the untested individuals and the most likely SARS-CoV-2 infection state was calculated for each of these individuals. For visualization of the prediction outcome, a heatmap was generated using ggplot2 after sorting the non-tested individuals by the predicted probability of SARS-CoV-2 infection as calculated for the Bayesian model.

# 133 **Results**

134 To obtain an overview of the subjective symptoms reported by SARS-CoV-2 infected 135 individuals, an online survey was performed. Invitations to the survey were published on 136 social media, and SARS-CoV-2 tested individuals were also directly invited to participate 137 when they received notification of their test results, or by subsequent invitation, by local 138 public health offices. Participants included both tested individuals, as well as non-tested 139 individuals, who were considered separately in the analysis of the survey. The characteristics 140 of the tested study population are represented in Table 1. In total, responses of 443 141 participants who had been tested for SARS-CoV-2 infection were included in the survey, 336 142 (75.8 %) had tested positive for SARS-CoV-2 infection, while 107 (24.2 %) of those 143 participants had tested negative. 293 (66.4 %) of the tested participants were recruited via the 144 public health office, whereas 150 (33.6 %) tested participants were recruited from social 145 media. 146 Of the 336 SARS-CoV-2 positive individuals, only 18 (5.3 %) reported no symptoms, 147 whereas 141 (42.2 %) and 102 (30.1 %) reported their symptoms as mild or moderate, 148 respectively, and 49 (14.7 %) reported their symptoms as severe. 20 (5.9 %) individuals were 149 treated in the hospital due to the SARS-CoV-2 infection, and another 6 (1.8 %) required 150 intensive care treatment. 151 The symptoms reported by the tested study population are shown as a heatmap in Figure 1, 152 frequencies of the symptoms reported by SARS-CoV-2 positive and negative individuals are 153 presented in Figure 2A. Clearly, a majority in both SARS-CoV-2 positive and negative 154 individuals reported general symptoms such as tiredness and lethargy. The presence of eye 155 symptoms in both groups was low, and also most nose symptoms were reported only by a 156 minority of participants. Interestingly, about two thirds of SARS-CoV-2 positive individuals 157 reported an impaired or lost sense of smell or taste. Dry cough was reported by almost 60% of

158 both SARS-CoV-2 positive and negative individuals, whereas most SARS-CoV-2 positive 159 individuals did not report other throat symptoms including throat pain. Approximately one 160 third of individuals reported breathing problems, and also diarrhea was reported by 161 approximately a third of SARS-CoV-2 positive and negative individuals. 162 The frequency of symptoms in SARS-CoV-2 positive and negative individuals were used to 163 calculate the odds ratios for the individual symptoms (Figure 2B). Since the distribution of 164 many symptoms was similar in SARS-CoV-2 positive and negative individuals, many odds 165 ratios are close to 1. Clearly, the highest odds ratios were observed for impaired or lost sense 166 of smell (estimate: 4.7; 90% confidence interval (CI): 2.8 - 8.1) and impaired or lost sense of 167 taste (4.3; 90% CI: 2.6 - 7.2), whereas the other nose symptoms as well as eve and throat 168 symptoms were found to have odds ratios below 1. The lowest odds ratios were observed for 169 throat pain and burning sensation in the throat. The odds ratio of dry coughing is also slightly 170 below 1 (0.9; 90% CI: 0.6 - 1.5), which may likely be an underestimation due to a bias in 171 eligibility criteria at the time of testing.

172 For the development of a prediction model, we performed a Bayesian regression analysis of 173 all symptoms and plotted them with their odds ratio in combination with the overall frequency (Figure 3A). As we have an imbalanced data set with less negative than positive tests, the 174 175 resulting model would have been biased towards positive predictions. To avoid this, we fitted 176 the model with two different approaches. In one, we increased the number of negatives by 177 bootstrapping to match the number of positives, in the other we decreased the number of 178 positives to match the number of negatives. Both approaches gave comparable results, but we 179 favored the first one as it uses all the available data and is less prone to the introduction of a 180 bias due to sample selection. For the final model, we selected symptoms that had marginal 181 posterior probabilities of 90% or more to be either positively or negatively associated with 182 positive or negative test results with mean posterior probabilities of > 0.5 or < -0.5 in the

Bayes regression analysis, and were reported by at least 20% of the positive or negative
individuals. We also performed a random forest regression analysis (Figure 3B), which
confirmed the importance of the selected symptoms.

186 Based on these analyses, we selected the ten symptoms impaired or lost sense of smell, throat 187 pain, loss of appetite, joint pain, runny nose, muscle pain, headache, fever higher than 188 38.5 °C, tiredness and chills. As stated above, the high representation of dry cough in SARS-189 CoV-2 uninfected symptomatic individuals is likely due to the fact that it was communicated 190 very early on as a typical symptom of SARS-CoV-2 infection, and was therefore a criterion 191 for testing. Furthermore, we observed a strong correlation between impaired or lost sense of 192 taste and sense of smell (Pearson's r = 0.72). Therefore, neither dry cough nor loss of taste 193 were included in the final Bayes model.

194 We used the selected ten symptoms to fit the final Bayesian regression model (Figure 4A). On

195 the tested cohort data set, the model gave an area under the receiver operating characteristic

196 curve of 0.80 (AUC; Figure 4B), a positive predictive value (PPV) of 0.80 (95% credible

197 interval: 0.74 - 0.84) and a negative predictive value (NPV) of 0.72 (95% credible interval:

 $198 \quad 0.68 - 0.77$ ). We applied the Bayesian model to the non-tested individuals who participated in

199 the survey. The characteristics of this second study population are represented in Table 1. In

200 total, responses of 520 participants who had not been tested for SARS-CoV-2 infection were

201 included in the survey. Using the Bayesian model described above, we calculated that 56

202 (10.8%) were SARS-CoV-2 positive with a probability of more than 75% (Figure 4C).

203 Another 84 individuals (16.2%) were predicted as SARS-CoV-2 positive with a probability

between 50% and 75%. For the other 380 individuals (73.1%), the probability of SARS-CoV-

205 2 infection based on the Bayesian model was less than 50%.

# 207 **Discussion**

208 The data presented here provide a very detailed picture of the symptoms experienced by209 SARS-CoV-2 infected individuals. To our knowledge, we are providing the most detailed210 symptoms overview reported so far, having queried 45 symptoms ranging from general

symptoms to specific eye, nose, throat, respiratory and gastrointestinal symptoms.

212 The data collected in this survey show that a range of symptoms is observed in a majority of

213 patients, such as an impaired or lost sense of smell or taste, tiredness, lethargy, loss of

appetite, joint or muscle pains and dry coughing. For some symptoms, we found surprisingly

215 low frequencies in infected individuals and therefore low odds ratios, including all throat

symptoms other than dry cough. Furthermore, only roughly one fifth of SARS-CoV-2

217 infected individuals experienced throat pain, which could be expected to be much higher since

218 virus is routinely identified in throat swabs, showing that it is indeed infecting throat tissue.

219 For some symptoms, a bias may have been introduced into the dataset at two levels: some

symptoms had been described early in the pandemic as typical for SARS-CoV-2 infection,

and have therefore been criteria for testing, and on the other hand, the presence of these

symptoms and the testing procedure itself may have increased the awareness of the affected

bias might exist for the symptoms "dry cough" and "difficulty breathing". The odds ratios

individuals and increased their motivation to participate in this study. We expect that such a

reported here may therefore be underestimates.

223

While many of the symptoms reported by SARS-CoV-2 positive individuals taken on their own are not useful for a prediction of SARS-CoV-2 infection, a prediction model based on 10 symptoms as we present here can provide a good estimate of the probability of a SARS-CoV-2 infection. The model therefore may provide useful guidance for personal behavior when symptoms are experienced as well as in the allocation of tests. It has to be noted though that while the positive predictive value of the model we describe here is rather high (0.80), the

232	negative predictive value is lower (0.72). When used in the future for personal risk
233	assessment, a predicted low probability of SARS-CoV-2 infection should therefore still be
234	interpreted with caution and personal protection measures should be maintained.
235	Other studies have been performed investigating symptoms of SARS-CoV-2 and their
236	predictive value. Studies in the early days of the COVID-19 pandemic were reporting
237	symptoms of hospitalized patients and thus missed the symptoms that are associated with
238	mild disease courses [5, 6, 16]. Since then, multiple other studies have been performed that
239	focused on the symptoms experienced by SARS-CoV-2 infected individuals at a community
240	level [8, 9, 17-21]. A large study has been performed using a mobile phone app that had more
241	than seven thousand SARS-CoV-2 tested participants from the United Kingdom and the
242	United States [19]. In this study, the authors found frequencies for the symptoms "loss of
243	smell and taste", "fever", "skipped meals" and "diarrhea" that are comparable to the
244	frequencies reported by us and reported positive odds ratios for these symptoms, with the
245	highest odds ratio for "loss of smell and taste". The authors report a similar frequency of
246	"persistent cough" in the SARS-CoV-2 positive individuals as we found for "dry cough"; in
247	contrast to our data, the frequency in SARS-CoV-2 negative individuals was lower than in our
248	cohort, leading to a low positive odds ratio for the persistent cough, in contrast to our
249	findings. The authors provided a prediction model based on age, sex, loss of smell and taste,
250	persistent cough, severe fatigue and skipped meals, which obtained a positive predictive value
251	of 0.69 and a negative predictive value of 0.75.
252	In another large study, only a small number of symptoms were surveyed: sore throat, cough,
253	shortness of breath, loss of smell or taste, and fever [20]. Interestingly, the authors report
254	distinctly lower frequencies for all these symptoms in their SARS-CoV-2 infected individuals,

255 which were mostly only half of the frequencies we observed in our study and as low as only

256 2% of respondents reporting a fever of 38°C or higher, compared to more than 33% observed

by us. This study also included a large number of individuals who were COVID-19
undiagnosed, who were ten times the number of diagnosed individuals, however more than
95% of the undiagnosed individuals reported to feel well and not have any of the queried
symptoms, creating an imbalance between the SARS-CoV-2 positive and negative study
population. The model proposed in that study that relies on this small number of symptoms
would likely prove less effective when applied to a cohort comprising more symptomatic
individuals.

In contrast to these two large-scale studies, we did not include age and sex in our models but included more symptoms, which resulted in a higher positive predictive value. Some of the symptoms included in our model are more subjective and may vary in strength, for example tiredness and loss of appetite. However, we think that modeling a prediction on this higher number of symptoms provides a more precise model that can be used for a first prediction of the probability of SARS-CoV-2 infection, guiding decisions for self-isolation and testing.

# 270 Conclusions

Our data shows that many symptoms reported by SARS-CoV-2 infected individuals are rather
unspecific and on their own are not amenable to a clear distinction of SARS-CoV-2 infection
from infections with other viruses causing common cold symptoms. Nevertheless, our
Bayesian model based on 10 symptoms provides a good prediction of probability of SARSCoV-2 infection. The model can provide a probability estimate and provide guidance in test
allocation where testing capacities are limited.

# 278 **Declarations**

## 279 Ethics approval and consent to participate

- 280 The study was approved by the local Ethics Committee of the Medical Faculty of the
- 281 University Duisburg-Essen (approval number 20-9233-BO)

#### 282 **Consent for publication**

283 Not applicable

## 284 Availability of data and materials

- 285 The datasets used and/or analyzed during the current study are available from the
- 286 corresponding author on reasonable request.

#### 287 Competing interests

288 The authors declare that they have no competing interests.

### 289 Funding

290 The study was supported by a grant from the Stiftung Universitätsmedizin Essen to WB.

#### 291 Authors' contributions

- HS recruited participants, analyzed data and contributed to writing the manuscript. DH
- analyzed data and contributed to writing the manuscript. WB conceived of the study, created
- the online survey, analyzed data and wrote the manuscript.

#### 295 Acknowledgements

- 296 The authors thank all study participants for taking the time to complete the online
- 297 questionnaire and contributing to our advancement in the recognition of SARS-CoV-2
- symptoms. The authors also thank the employees of the public health offices in Hamm

- 299 (Germany), Soest (Germany), Hochsauerlandkreis (Germany) and Dr. Hüning and nurses of
- 300 the SARS-CoV-2 treatment center in Lünen (Germany) for distributing invitations to the
- 301 online survey.

#### References 302

303	1.	Undiagnosed Pneumonia - China (Hubei): Request for Information
304		[https://promedmail.org/promed-post/?id=6864153%20#COVID19]
305	2.	WHO Director-General's statement on IHR Emergency Committee on Novel
306		Coronavirus (2019-nCoV) [https://www.who.int/dg/speeches/detail/who-director-
307		general-s-statement-on-ihr-emergency-committee-on-novel-coronavirus-(2019-ncov)]
308	3.	Spiteri G, Fielding J, Diercke M, Campese C, Enouf V, Gaymard A, Bella A,
309		Sognamiglio P, Sierra Moros MJ, Riutort AN et al: First cases of coronavirus
310		disease 2019 (COVID-19) in the WHO European Region, 24 January to 21
311		February 2020. Euro Surveill 2020, 25(9).
312	4.	Weekly Operational Update on COVID-19, 6 November 2020
313		[https://www.who.int/publications/m/item/weekly-operational-update-on-covid-19
314		6-november-2020]
315	5.	Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC
316	0.	et al: Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med
317		2020, <b>382</b> (18):1708-1720.
318	6.	Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X <i>et al</i> :
319	0.	Clinical features of patients infected with 2019 novel coronavirus in Wuhan,
320		China. Lancet 2020, <b>395</b> (10223):497-506.
321	7.	Miyamae Y, Hayashi T, Yonezawa H, Fujihara J, Matsumoto Y, Ito T, Tsubota T,
322		Ishii K: Duration of viral shedding in asymptomatic or mild cases of novel
323		coronavirus disease 2019 (COVID-19) from a cruise ship: A single-hospital
324		experience in Tokyo, Japan. Int J Infect Dis 2020, 97:293-295.
325	8.	Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L, Rusconi S,
326		Gervasoni C, Ridolfo AL, Rizzardini G <i>et al</i> : Self-reported Olfactory and Taste
327		Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A
328		<b>Cross-sectional Study</b> . <i>Clin Infect Dis</i> 2020, <b>71</b> (15):889-890.
329	9.	Maechler F, Gertler M, Hermes J, van Loon W, Schwab F, Piening B, Rojansky S,
330		Hommes F, Kausch F, Lindner AK <i>et al</i> : <b>Epidemiological and clinical</b>
331		characteristics of SARS-CoV-2 infections at a testing site in Berlin, Germany,
332		March and April 2020-a cross-sectional study. Clin Microbiol Infect 2020.
333	10.	Liaw A, Wiener M: Classification and Regressoin by randomForest. R News 1002,
334		<b>2</b> (3):18-22.
335	11.	rstanarm: Bayesian applied regression modeling via Stan. R package version
336		2.21.1 [https://mc-stan.org/rstanarm]
337	12.	Gabry J, Simpson D, Vehtari A, Betancour M, Gelman A: Visualization in Bayesian
338		workflow. Journal of the Royal Statistical Society Series A 2019, 182(2):389-402.
339	13.	Sing T, Sander O, Beerenwinkel N, Lengauer T: ROCR: visualizing classifier
340		performance in <b>R</b> . <i>Bioinformatics</i> 2005, <b>21</b> (20):3940-3941.
341	14.	Voila
342		[https://mybinder.org/v2/gh/niklastoe/classifier_metric_uncertainty/master?urlpath=%
343		2Fvoila%2Frender%2Finteractive_notebook.ipynb]
344	15.	Toetsch N, Hoffmann D: Classifier uncertainty: evidence, potential impact, and
345		probabilistic treatment. In. arXiv; 2020.
346	16.	Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y et al:
347		Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus
348		pneumonia in Wuhan, China: a descriptive study. Lancet 2020, 395(10223):507-
349		513.

medRxiv preprint doi: https://doi.org/10.1101/2020.11.25.20236752; this version posted November 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

350	17.	Ahamad MM, Aktar S, Rashed-Al-Mahfuz M, Uddin S, Lio P, Xu H, Summers MA,
351		Quinn JMW, Moni MA: A machine learning model to identify early stage
352		symptoms of SARS-Cov-2 infected patients. Expert Syst Appl 2020, 160:113661.
353	18.	Menni C, Sudre CH, Steves CJ, Ourselin S, Spector TD: Quantifying additional
354		<b>COVID-19 symptoms will save lives</b> . <i>Lancet</i> 2020, <b>395</b> (10241):e107-e108.
355	19.	Menni C, Valdes AM, Freidin MB, Sudre CH, Nguyen LH, Drew DA, Ganesh S,
356		Varsavsky T, Cardoso MJ, El-Sayed Moustafa JS et al: Real-time tracking of self-
357		reported symptoms to predict potential COVID-19. Nat Med 2020, 26(7):1037-
358		1040.
359	20.	Shoer S, Karady T, Keshet A, Shilo S, Rossman H, Gavrieli A, Meir T, Lavon A,
360		Kolobkov D, Kalka I et al: A prediction model to prioritize individuals for SARS-
361		<b>CoV-2</b> test built from national symptom surveys. <i>Med</i> ( <i>N Y</i> ) 2020.
362	21.	Sudre CH, Lee K, Ni Lochlainn M, Varsavsky T, Murray B, Graham MS, Menni C,
363		Modat M, Bowyer RCE, Nguyen LH et al: Symptom clusters in Covid19: A
364		potential clinical prediction tool from the COVID Symptom study app. medRxiv
365		2020:2020.2006.2012.20129056.
366		

#### **Tables** 367

#### Table 1. Characteristics of study cohort. 368

	SARS-CoV-2 positive n (% of total)	SARS-CoV-2 negative n (% of total)	untested n (% of total)
number	336	107	520
age (years)			
18 – 29	55 (16.4%)	18 (16.8%)	92 (17.7%)
30 - 39	45 (13.4%)	36 (33.6 %)	178 (34.2%)
40 - 49	61 (18.2%)	26 (24.3%)	126 (24.2%)
50 - 59	118 (35.1%)	19 (17.8%)	88 (16.9%)
60 - 69	41 (12.2%)	7 (6.5%)	29 (5.6%)
70 - 79	9 (2.7%)	1 (0.94%)	5 (1.0%)
> 80	7 (2.1%)	0 (0%)	2 (0.4%)
gender			
female	189 (56.3%)	81 (75.7%)	409 (78.7%)
male	147 (43.8%)	25 (23.4%)	109 (21.0%)
diverse	0 (0%)	1 (0.9%)	2 (0.4%)
smoking	13.1%	23.4%	30.2%
hayfever*	19.1%	23.4%	25.6%

\* hayfever relevant at the time of infection 369

# 371 Figure Legends

#### 372 Figure 1 Heatmap of symptoms reported by SARS-CoV-2 positive and negative

### 373 individuals.

374 Symptoms reported by SARS-CoV-2 positive (top) and SARS-CoV-2 negative individuals

375 (bottom). Subjects were sorted according to responses concerning severity and presence of

- 376 fever. feverish/not feverish: subjective judgement, participant did not measure their body
- 377 temperature.
- 378 Figure 2 Frequencies and odds ratio of symptoms

379 (A) Frequencies for each symptom were calculated for SARS-CoV-2 positive and for SARS-

380 CoV-2 negative individuals, respectively. (B) Odds ratios of individual symptoms and 90%

381 confidence intervals.

## 382 Figure 3 Bayesian regression and Random Forest-based selection of modelling factors


383 (A) For visual selection of symptoms for predictive modeling, the frequency of symptoms in 384 SARS-CoV-2 negative individuals was plotted against the frequency in SARS-CoV-2 positive 385 individuals for individual symptoms, odds ratio (OR) was visualized as dot size, Bayes model 386 mean posterior probability estimate was visualized as color as indicated. Selected symptoms 387 in bold letters. (B) Random Forest logistic regression analysis was performed to identify 388 individual symptoms with importance for the development of a predictive model; the figure 389 shows the mean decrease of the Gini index for the individual symptoms. Selected symptoms 390 in bold letters.

# Figure 4 Heatmap of predicted probability of SARS-CoV-2 infection and of symptoms reported by non-tested individuals

393 (A) Bayesian regression analysis was performed using the indicated symptoms as priors,

394 mean estimates and 90% highest posterior density intervals are shown. (B) Performance of the

- 395 Bayesian model and the Random Forest analysis are shown as receiver operating
- 396 characteristic curves; AUC (area under the curve), PPV (positive predictive value) and NPV
- 397 (negative predictive value) with 95% credibility intervals of the Bayesian model on the model
- 398 dataset of tested individuals are shown. (C) The dataset of non-tested individuals (n = 520)
- 399 was submitted to the Bayesian model, and symptoms are shown for all individuals sorted from
- 400 highest predicted probability ( $p_B = Bayesian model prediction; top$ ) to lowest predicted
- 401 probability (bottom).




SARS-CoV-2 test

negative positive

severity of symptoms

none mild intermediate severe hospitalization intensive care

fever



pollen allergy no

yes


non-relevant


presence of specific symptom

no yes

Figure 2

A	frequency in SARS-CoV2+ [%] S		Odds ratio • • • • • • • • • •	ه. ۹. ۹.
fever > 38.5 °C tiredness lethargy loss of appetite headache joint pain muscle pain chills	6 62.8 7 58.04 9 46.13 9 51.19 1 41.96 1 38.99	22.43       -         59.81       -         51.4       -         24.3       -         65.42       -         27.1       -         28.97       -         28.04       -		
sweating feeling cold vertige	21.43	20.56 22.43 21.5		
itching eyes foreign body sensation dry eyes watery eyes conjunctivitis light sensitivity blurred vision clouded vision	3.87           8.63           4.76           2.08           4.04           5.06	14.02       -         10.28       -         17.76       -         9.35       -         5.61       -         12.15       -         5.61       -         1.87       -		
sneezing blocked nose phlegmy nose runny nose itching nose burning nose loss of smel loss of taste	21.73       9.82       22.32       5.06       3.57       58.93	28.04 26.17 12.15 32.71 6.54 4.67 23.36 27.1		
dry cough phlegmy cough bloody cough throat pain sore throat painful swallowing phlegmy throat burning throat throat tightness	8.63           0.6           20.24           30.95           8.04           10.42           4.17	58.88       -         16.82       -         0.93       -         43.93       -         39.25       -         18.69       -         17.76       -         14.95       -         16.82       -		
difficulty breathing chest tightness painful breathing chest pain	32.44 25 6.55	38.32 27.1 14.95 14.02		frequency [%]
nausea vomiting diarrhea abdominal pain abdominal cramps	2.08 32.44 7.44	16.82 2.8 28.97 8.41 5.61		-20 -40 -60







- 0.25

\_ \_0.0

